Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Sulbactam Sodium

FDA-approved product (injectable, injection).

Registered studies
50+
Lab records
20
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Sulbactam Sodium
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Bacterial disease
  • Infection

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Beta-lactamase inhibitors
Anti-infective classification
Classified as an existing antimicrobial.WHO ATC J01CG01

Repurposing investigation

Sulbactam Sodium is already an antimicrobial, so it is not counted among the repurposing candidates. Its AI-predicted activity is shown below for reference.

AI-predicted activity

AI prediction · nothing measured
  • MRSA6.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • E. coli64.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • K. pneumoniae18.1% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • M. tuberculosis26.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

  • MRSA: measured active in 2 of 5 lab records
  • E. coli: measured active in 10 of 13 lab records
  • K. pneumoniae: measured active in 0 of 2 lab records
Open Sulbactam Sodium in ChEMBL Registered studies below
Show the 20 laboratory records, with sources

Loading records…

“Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-4.7 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-5.8 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-6.1 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-4.6 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Sulbactam Sodium with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Impact of Hypoalbuminemia on Cefoperazone/Sulbactam Induced Coagulopathy in Post-Operative Surgical Patients

    NCT07773584 · start 2027-04

    Registered record
    Registry ID
    NCT07773584
    Conditions
    Cefoperazone/Sulbactam Induced Coagulopayjy
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Not yet recruiting
    Start
    2027-04
    Completion
    2027-10
    Enrolment
    108

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCefoperazone/Sulbactam Induced Coagulopayjy
    InterventionNot recorded
    PhaseNot recorded
    Registry statusNot yet recruiting

  • Assessing Role of Probiotics in Children Aged 6-36 Months Treated for Pneumonia

    NCT07399717 · start 2026-11-01

    Registered record
    Registry ID
    NCT07399717
    Conditions
    Pneumonia; Pneumonia in Children
    Interventions
    Placebo; Navax; Navax-PregMom
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Not yet recruiting
    Start
    2026-11-01
    Completion
    2027-12-30
    Enrolment
    330

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPneumonia; Pneumonia in Children
    InterventionPlacebo; Navax; Navax-PregMom
    PhaseNot applicable
    Registry statusNot yet recruiting

  • One Versus Five Days of Antibiotics After Appendectomy

    NCT07563933 · start 2026-05-01

    Registered record
    Registry ID
    NCT07563933
    Conditions
    Post Operative Antibiotic Therapy of Acute Appendicitis
    Interventions
    a single day (24 hours) post operative
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Not yet recruiting
    Start
    2026-05-01
    Completion
    2027-04-30
    Enrolment
    200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPost Operative Antibiotic Therapy of Acute Appendicitis
    Interventiona single day (24 hours) post operative
    PhaseNot applicable
    Registry statusNot yet recruiting

  • Cefotetan Therapy for Escherichia Coli Infections

    NCT07318584 · start 2026-03

    Registered record
    Registry ID
    NCT07318584
    Conditions
    E Coli Infection; ESBL Producing E.Coli
    Interventions
    Cefotetan; Carbapenems; Beta Lactam Antibiotics
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Not yet recruiting
    Start
    2026-03
    Completion
    2028-08
    Enrolment
    84

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionE Coli Infection; ESBL Producing E.Coli
    InterventionCefotetan; Carbapenems; Beta Lactam Antibiotics
    PhasePhase 2
    Registry statusNot yet recruiting

  • Sulbactam-Durlobactam in CRAB Infection: A Real-World Cohort Study

    NCT07601711 · start 2025-11-11

    Registered record
    Registry ID
    NCT07601711
    Conditions
    Carbapenem-Resistant Acinetobacter Baumannii Infection; Bloodstream Infection; Pneumonia; Sepsis
    Interventions
    Sulbactam-Durlobactam
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Recruiting
    Start
    2025-11-11
    Completion
    2027-11-11
    Enrolment
    200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCarbapenem-Resistant Acinetobacter Baumannii Infection; Bloodstream Infection; Pneumonia; Sepsis
    InterventionSulbactam-Durlobactam
    PhaseNot recorded
    Registry statusRecruiting

  • Optimising TREATment for Severe Gram-Negative Bacterial Infections

    NCT07004049 · start 2025-04-21

    Registered record
    Registry ID
    NCT07004049
    Conditions
    Bloodstream Infection; Ventilator Associated Bacterial Pneumonia; Hospital Acquired Bacterial Pneumonia; Carbapenem Resistant Bacterial Infection; Multidrug Resistance
    Interventions
    Colistin/Polymyxin B + Sulbactam; Colistin/Polymyxin B + Tigecycline/Eravacycline; Colistin/Polymyxin B + Meropenem; Ceftazidime-avibactam + Sulbactam; Ceftazidime-avibactam + Fosfomycin; Ceftazidime-avibactam; Ceftazidime-avibactam + Aztreonam; Ceftazidime-avibactam + Colistin/Polymyxin B; High-dose meropenem; Meropenem + Fosfomycin; Meropenem-vaborbactam; Cefiderocol; Ceftolozane-tazobactam; Ceftolozane-tazobactam + Meropenem
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2025-04-21
    Completion
    2028-12-31
    Enrolment
    600

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBloodstream Infection; Ventilator Associated Bacterial Pneumonia; Hospital Acquired Bacterial Pneumonia; Carbapenem Resistant Bacterial Infection +1 more
    InterventionColistin/Polymyxin B + Sulbactam; Colistin/Polymyxin B + Tigecycline/Eravacycline; Colistin/Polymyxin B + Meropenem; Ceftazidime-avibactam + Sulbactam +10 more
    PhasePhase 4
    Registry statusRecruiting

  • Colistin Versus Colistin Combined With Cefoperazone-sulbactam for Multiresistant Acinetobactor Baumannii Ventilator-associated Pneumonia Treatment

    NCT07671755 · start 2025-02-01

    Registered record
    Registry ID
    NCT07671755
    Conditions
    Clinical Response; Radiological Response
    Interventions
    colistin plus cefoperazone-sulbactam combination group; Colistin
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2025-02-01
    Completion
    2026-04-30
    Enrolment
    80

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionClinical Response; Radiological Response
    Interventioncolistin plus cefoperazone-sulbactam combination group; Colistin
    PhaseNot applicable
    Registry statusCompleted

  • Therapeutic Options for CRAB

    NCT06440304 · start 2025-01-30

    Registered record
    Registry ID
    NCT06440304
    Conditions
    Infections, Bacterial; Sepsis Bacterial
    Interventions
    Fosfomycin; Eravacycline; ampicillin/sulbactam
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2025-01-30
    Completion
    2027-02
    Enrolment
    108

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInfections, Bacterial; Sepsis Bacterial
    InterventionFosfomycin; Eravacycline; ampicillin/sulbactam
    PhasePhase 4
    Registry statusRecruiting

  • Group B Streptococcus Infection and PROM Incidince

    NCT06735703 · start 2024-12-25

    Registered record
    Registry ID
    NCT06735703
    Conditions
    Premature Rupture of Fetal Membranes; Group B Streptococcal Infection
    Interventions
    To provide ampicillin sulbactam to pregnant women with premature rupture of membrane
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Not yet recruiting
    Start
    2024-12-25
    Completion
    2026-01-09
    Enrolment
    150

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPremature Rupture of Fetal Membranes; Group B Streptococcal Infection
    InterventionTo provide ampicillin sulbactam to pregnant women with premature rupture of membrane
    PhaseNot recorded
    Registry statusNot yet recruiting

  • Effects of Different Antibiotic Regimens in Preterm Premature Rupture of Membranes

    NCT07148622 · start 2024-10-01

    Registered record
    Registry ID
    NCT07148622
    Conditions
    Preterm Premature Rupture of Membranes (PPROM); Prophylaxis; Perinatal Outcomes
    Interventions
    Antibiotic regimen 1: sulbactam + ampicillin + azithromycin; Antibiotic regimen 2: ceftriaxone + clarithromycin + amoxicillin
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2024-10-01
    Completion
    2025-08-10
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPreterm Premature Rupture of Membranes (PPROM); Prophylaxis; Perinatal Outcomes
    InterventionAntibiotic regimen 1: sulbactam + ampicillin + azithromycin; Antibiotic regimen 2: ceftriaxone + clarithromycin + amoxicillin
    PhaseNot applicable
    Registry statusCompleted

  • A Study on the Combination Therapy of Eravacycline for Treating Carbapenem-Resistant Acinetobacter Baumannii Pneumonia

    NCT06670872 · start 2024-10

    Registered record
    Registry ID
    NCT06670872
    Conditions
    Pneumonitis; Acinetobacter Baumannii
    Interventions
    Eravacycline combination therapy group
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Not yet recruiting
    Start
    2024-10
    Completion
    2026-10
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPneumonitis; Acinetobacter Baumannii
    InterventionEravacycline combination therapy group
    PhaseNot recorded
    Registry statusNot yet recruiting

  • Short Versus Standard of Care Antibiotic Duration for Children Hospitalized for CAP

    NCT06494072 · start 2024-08-22

    Registered record
    Registry ID
    NCT06494072
    Conditions
    Community Acquired Pneumonia in Children
    Interventions
    Ampicillin for Injection; Ceftriaxone for Injection; Amoxicillin; Ampicillin / Sulbactam Injection; Amoxicillin-clavulanate; Clindamycin; Cefprozil; Levofloxacin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2024-08-22
    Completion
    2028-05
    Enrolment
    236

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCommunity Acquired Pneumonia in Children
    InterventionAmpicillin for Injection; Ceftriaxone for Injection; Amoxicillin; Ampicillin / Sulbactam Injection +4 more
    PhasePhase 4
    Registry statusRecruiting

  • Concentration Monitoring of Anti-infective Drugs in Human Cerebrospinal Fluid and Its Clinical Application

    NCT06729619 · start 2024-06-03

    Registered record
    Registry ID
    NCT06729619
    Conditions
    Intracranial Infection; Central Infection
    Interventions
    The concentration of anti-infective drugs in blood and cerebrospinal fluid will be determined.
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Active not recruiting
    Start
    2024-06-03
    Completion
    2027-12-31
    Enrolment
    200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionIntracranial Infection; Central Infection
    InterventionThe concentration of anti-infective drugs in blood and cerebrospinal fluid will be determined.
    PhaseNot recorded
    Registry statusActive not recruiting

  • Biomarkers & Infection After Prophylactic Antibiotic in Cardiac Implantable Electronic Device Implantation

    NCT06448624 · start 2024-04-01

    Registered record
    Registry ID
    NCT06448624
    Conditions
    Heart Block; CIED Related Infection; CIED-related Infections; Antibiotic Prophylaxis; Biomarkers
    Interventions
    Ampicillin sulbactam 3 days; Placebo 3 days
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2024-04-01
    Completion
    2025-01-31
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHeart Block; CIED Related Infection; CIED-related Infections; Antibiotic Prophylaxis +1 more
    InterventionAmpicillin sulbactam 3 days; Placebo 3 days
    PhasePhase 4
    Registry statusCompleted

  • Clarithromycin Treatment to Prevent Sepsis Progression in CAP (REACT)

    NCT06294600 · start 2024-02-12

    Registered record
    Registry ID
    NCT06294600
    Conditions
    Community-acquired Pneumonia
    Interventions
    Clarithromycin 500mg; Tablets
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2024-02-12
    Completion
    2026-07-30
    Enrolment
    330

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCommunity-acquired Pneumonia
    InterventionClarithromycin 500mg; Tablets
    PhasePhase 3
    Registry statusRecruiting